Showing results (151-160 of 169) with videos related to
Sort By:
Pageof 17
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 4, 2017
Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancerA Poveda, J M Del Campo, I Ray-Coquard, et al.Anti-Cancer Drugs|April 23, 2019
Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancerIgnacio Romero, Pedro Mallol, Ana Santaballa, et al.The Lancet. Oncology|July 21, 2018
Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trialAmit M Oza, Ursula A Matulonis, Susanne Malander, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 17, 2016
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trialP M Clement, T Gauler, J P Machiels, et al.Gynecologic Oncology|January 8, 2016
BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 studyPhilipp Harter, Toby Johnson, Dominique Berton-Rigaud, et al.The Lancet. Oncology|April 21, 2015
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trialJean-Pascal H Machiels, Robert I Haddad, Jérôme Fayette, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 8, 2019
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA TrialJosep M Del Campo, Ursula A Matulonis, Susanne Malander, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE)Christian Kurzeder, Isabel Bover, Frederik Marmé, et al.Gynecologic Oncology|September 15, 2019
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancerI Vergote, A du Bois, A Floquet, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancerE E W Cohen, L F Licitra, B Burtness, et al.Pageof 17